Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tonix Pharmaceuticals

40.65
+2.245.83%
Post-market: 40.25-0.4000-0.98%17:49 EDT
Volume:704.15K
Turnover:28.44M
Market Cap:297.75M
PE:-0.23
High:41.77
Open:38.11
Low:38.06
Close:38.41
Loading ...

BRIEF-Tonix Pharmaceuticals Announces First Patient Dosed In Phase 2 Oasis Study Of TNX-102 SL For Reduction Of Acute Stress Reaction

Reuters
·
21 May

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 Oasis Study of Tnx-102 Sl for Reduction of Acute Stress Reaction

THOMSON REUTERS
·
21 May

Tonix Pharmaceuticals Holding Corp - Topline Results Expected in Second Half of 2026

THOMSON REUTERS
·
21 May

CEO Seth Lederman Reports Acquisition of Common Shares in Tonix Pharmaceuticals Holding Corp

Reuters
·
16 May

Noble Financial Reaffirms Their Buy Rating on Tonix Pharma (TNXP)

TIPRANKS
·
14 May

BRIEF-Tonix Pharmaceuticals Announces Appointment Of Joseph Hand, Esq., As General Counsel And Executive Vice President Of Operations

Reuters
·
14 May

Tonix Pharmaceuticals appoints Hand as General Counsel, EVP of Operations

TIPRANKS
·
14 May

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

THOMSON REUTERS
·
14 May

Press Release: Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

Dow Jones
·
14 May

Tonix Pharmaceuticals Holding Corp reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

Tonix Pharmaceuticals Q1 EPS $(2.84) Beats $(3.37) Estimate, Sales $2.43M Miss $2.55M Estimate

Benzinga
·
13 May

Tonix Pharmaceuticals: Current Cash Sufficient to Fund Operations Into Q2 of 2026

THOMSON REUTERS
·
13 May

Tonix Pharmaceuticals Holding Corp expected to post a loss of $3.23 a share - Earnings Preview

Reuters
·
10 May

Tonix Pharmaceuticals Held Annual Shareholders Meeting

Reuters
·
09 May

Tonix Pharmaceuticals Unveils Presentation on Advancements in Therapeutics for Pain and Neurologic Conditions

Reuters
·
01 May

BRIEF-Tonix Pharmaceuticals Holding Corp - Discontinued Enrollment And Terminated Phase 2 Catalyst Study - SEC Filing

Reuters
·
26 Apr

BRIEF-Tonix Pharmaceuticals Presented Data On Potential Mpox Vaccine TNX-801 At World Vaccine Congress Washington 2025

Reuters
·
24 Apr

BRIEF-Tonix Pharmaceuticals Announces Oral Presentation And Panel Participation At The World Vaccine Congress Washington 2025

Reuters
·
16 Apr

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

THOMSON REUTERS
·
16 Apr

BRIEF-Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

Reuters
·
09 Apr